Original articles

Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study)

M Turpeinen¹, K Nikander², A S Pelkonen¹, P Syvänen¹, R Sorva¹, H Raitio¹, P Malmberg¹, K Juntunen-Backman¹, T Haahtela¹

¹ Department of Allergy, Helsinki University Hospital, Finland
² AstraZeneca R&D, Lund, Sweden

Dr M Turpeinen, Skin and Allergy Hospital, Department of Allergy, Helsinki University Hospital, Meilahdentie 2, FIN-00250 Helsinki, Finland; markku.t.turpeinen{at}hus.fi

Objective: To compare the effect of inhaled budesonide given daily or as-needed on mild persistent childhood asthma.

Patients, design and interventions: 176 children aged 5–10 years with newly detected asthma were randomly assigned to three treatment groups: (1) continuous budesonide (400 µg twice daily for 1 month, 200 µg twice daily for months 2–6, 100 µg twice daily for months 7–18); (2) budesonide, identical treatment to group 1 during months 1–6, then budesonide for exacerbations as needed for months 7–18; and (3) disodium cromoglycate (DSCG) 10 mg three times daily for months 1–18. Exacerbations were treated with budesonide 400 µg twice daily for 2 weeks.

Main outcome measures: Lung function, the number of exacerbations and growth.

Results: Compared with DSCG the initial regular budesonide treatment resulted in a significantly improved lung function, fewer exacerbations and a small but significant decline in growth velocity. After 18 months, however, the lung function improvements did not differ between the groups. During months 7–18, patients receiving continuous budesonide treatment had significantly fewer exacerbations (mean 0.97), compared with 1.69 in group 2 and 1.58 in group 3. The number of asthma-free days did not differ between regular and intermittent budesonide treatment. Growth velocity was normalised during continuous low-dose budesonide and budesonide therapy given as needed. The latter was associated with catch-up growth.

Conclusions: Regular use of budesonide afforded better asthma control but had a more systemic effect than did use of budesonide as needed. The dose of ICS could be reduced as soon as asthma is controlled. Some children do not seem to need continuous ICS treatment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Atoms

Howard Bauchner
Arch. Dis. Child. 2008 93: 1. [Extract] [Full Text] [PDF]

Do the benefits of daily inhaled steroid treatment of mild asthma outweigh the risks?

Søren Pedersen
Arch. Dis. Child. 2008 93: 644-645. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Montuschi, P., Pagliari, G., Fuso, L. (2009). Pharmacotherapy of asthma: regular treatment or on demand?. Ther Adv Respir Dis 3: 175-191 [Abstract]  
• Papi, A., Caramori, G., Adcock, I. M., Barnes, P. J. (2009). Rescue Treatment in Asthma: More Than As-Needed Bronchodilation. Chest 135: 1628-1633 [Abstract] [Full Text]  
• Bush, A. (2009). Update in Pediatric Lung Disease 2008. Am. J. Respir. Crit. Care Med. 179: 637-649 [Full Text]  

eLetters:

Read all eLetters

Use of appropriate inhaler devices for optimal delivery of inhaled corticosteroids

Samatha Sonnappa

ADC Online, 30 Jul 2008 [Full text]

Appropriate inhaler devices for children with asthma

Markku T Turpeinen, et al.

ADC Online, 3 Sep 2008 [Full text]

Re: Use of appropriate inhaler devices for optimal delivery of inhaled corticosteroids

Steve Turner

ADC Online, 1 Sep 2008 [Full text]

Use of approriate inhaler devices for optimal delivery of inhaled corticosteroids

Markku T Turpeinen

ADC Online, 4 Sep 2008 [Full text]